Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model
ED Pieterman, S van den Berg… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Improvements in the translational value of preclinical models can allow more-successful and
more-focused research on shortening the duration of tuberculosis treatment. Although the …
more-focused research on shortening the duration of tuberculosis treatment. Although the …
Efficacy versus hepatotoxicity of high-dose rifampin, pyrazinamide, and moxifloxacin to shorten tuberculosis therapy duration: there is still fight in the old warriors yet!
S Srivastava, D Deshpande… - Clinical Infectious …, 2018 - academic.oup.com
Background One approach that could increase the efficacy and reduce the duration of
antituberculosis therapy is pharmacokinetics/pharmacodynamics-based optimization of …
antituberculosis therapy is pharmacokinetics/pharmacodynamics-based optimization of …
The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as …
GL Drusano, N Sgambati, A Eichas, DL Brown… - MBio, 2010 - Am Soc Microbiol
Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis.
Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin …
Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin …
The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens
D Chilukuri, O McMaster, K Bergman… - Clinical Infectious …, 2015 - academic.oup.com
Tuberculosis remains a serious public health challenge, with the global prevalence of active
disease estimated at 8.6 million and the mortality rate at 1.3 million deaths per year [1]. In …
disease estimated at 8.6 million and the mortality rate at 1.3 million deaths per year [1]. In …
Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin
DA Aguilar‐Ayala, F Sanz‐García… - British Journal of …, 2024 - Wiley Online Library
Aims: The hollow-fibre system for tuberculosis (HFS-TB) is a preclinical model qualified by
the European Medicines Agency to underpin the anti-TB drug development process. It can …
the European Medicines Agency to underpin the anti-TB drug development process. It can …
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
T Gumbo, S Srivastava, D Deshpande… - Journal of …, 2023 - academic.oup.com
Background The hollow-fibre system model of tuberculosis (HFS-TB) has been endorsed by
regulators; however, application of HFS-TB requires a thorough understanding of intra-and …
regulators; however, application of HFS-TB requires a thorough understanding of intra-and …
Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm
T Gumbo, JG Pasipanodya… - Clinical Infectious …, 2015 - academic.oup.com
Background. The hollow fiber system model of tuberculosis (HFS-TB) is designed to perform
pharmacokinetics/pharmacodynamics (PK/PD) experiments, and hence the design of …
pharmacokinetics/pharmacodynamics (PK/PD) experiments, and hence the design of …
[HTML][HTML] Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
IM Rosenthal, M Zhang, KN Williams… - PLoS …, 2007 - journals.plos.org
Background Availability of an ultra-short-course drug regimen capable of curing patients
with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because …
with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because …
The role of novel approaches and new findings in the pharmacology of tuberculosis medicines in improving treatment outcomes
D Falzon, E Jaramillo, C Gilpin… - Clinical Infectious …, 2018 - academic.oup.com
In its 2017 report on the status of tuberculosis in the world, the World Health Organization
(WHO) estimated that tuberculosis causes about 1.7 million deaths each year, making it the …
(WHO) estimated that tuberculosis causes about 1.7 million deaths each year, making it the …
[HTML][HTML] Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting
Y Park, PM Tung, NK Anh, YS Cho… - Journal of Korean …, 2024 - ncbi.nlm.nih.gov
Background The hollow-fiber infection model (HFIM) is a valuable tool for evaluating
pharmacokinetics/pharmacodynamics relationships and determining the optimal antibiotic …
pharmacokinetics/pharmacodynamics relationships and determining the optimal antibiotic …